Data from Hamilton Health Sciences Broaden Understanding of Carcinomas (Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma).

A recent meta-analysis conducted by researchers at Hamilton Health Sciences in Canada evaluated the efficacy and safety of lenvatinib, both as a monotherapy and in combination with other tyrosine kinase inhibitors, for the treatment of metastatic renal cell carcinoma (RCC). The study found that lenvatinib, especially when used in combination therapies, significantly improved progression-free survival (PFS) and overall survival (OS) compared to other tyrosine kinase inhibitors. While lenvatinib was associated with various adverse events, its safety profile was comparable to other TKIs. This research provides valuable insights into the potential benefits of lenvatinib in treating metastatic RCC. [Extracted from the article]